PXS-5505 free base
Based on 3 publication(s) in Google Scholar
PXS-5505 free base (LOX-IN-3) is an orally active lysyl oxidase (LOX) inhibitor. PXS-5505 free base can be used for fibrosis, cancer and angiogenesis research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.36%
- CAS No.: 2409963-83-1
- Formule: C13H13FN2O2S
- Masse moléculaire:280.32
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Neuronal Signaling Compound Library
HY-L013
-
Anti-Cancer Compound Library
HY-L025
-
Reprogramming Compound Library
HY-L039
-
Orally Active Compound Library
HY-L061
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-Obesity Compound Library
HY-L087
-
Mitochondria-Targeted Compound Library
HY-L089
-
Antidepressant Compound Library
HY-L108
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) PXS-5505 free base
More
Activité biologique
IC50: <1 μM (human LOXL2), <10 μM (bovine LOX)[1]
PXS-5505 free base (Compound 33) inhibits the bovine LOX and human LOXL2 activities with IC50 values of <10 μM and <1 μM, respectively[1].
PXS-5505 free base exhibits sustained inhibition of LOXL1 and LOXL2[1].
PXS-5505 free base is less active against SSAO/VAP-1 and MAO-B activities[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
PXS-5505 free base (10 mg/kg; orally; daily for 14 days) reduces kidney fibrosis in unilateral ureteric obstruction (UUO) mice model[1].
PXS-5505 free base (15 mg/kg; orally; daily for 21 days) reduces lung fibrosis in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats[1]
-
Dosage:30 mg/kg
-
Administration:Oral administration, single dose
-
Result:Completely abolished lysyl oxidase activity. Plasma concentrations of tested compound are far below the IC50 after 8 hours, the half-life of recovery is between 2-3 days (ear) and 24 hours (aorta).
-
Animal Model:Unilateral ureteric obstruction (UUO) model of acute kidney fibrosis in mice[1]
-
Dosage:10 mg/kg
-
Administration:Oral gavage, daily for 14 days
-
Result:Increased kidney weight and thickness and reduced the area of fibrosis.
-
Animal Model:C57Bl/6 mice, Bleomycin-induced lung fibrosis model
-
Dosage:15 mg/kg
-
Administration:Oral gavage, daily for 21 days
-
Result:Significantly reduced the Ashcroft score and the lung weight.
Chemical Information
-
CAS No. 2409963-83-1
-
Appearance Solid
-
Masse moléculaire 280.32
-
Formule C13H13FN2O2S
-
Color White to off-white
-
SMILES
NC/C=C(F)/CS(=O)(C1=C2N=CC=CC2=CC=C1)=O
-
Synonyms
LOX-IN-3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma. [Abstract]2026 Feb 18. PMID: 41706704 -
iScience
MFAP5+ synovial fibroblasts drive LOX upregulation to promote osteoarthritis progression. [Abstract]2026 Jun 11;29(7):116286. PMID: 42325584 -
Solvant et solubilité
DMSO : 100 mg/mL (356.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.42 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.42 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5674 mL | 17.8368 mL | 35.6735 mL | 89.1838 mL |
| 5 mM | 0.7135 mL | 3.5674 mL | 7.1347 mL | 17.8368 mL | |
| 10 mM | 0.3567 mL | 1.7837 mL | 3.5674 mL | 8.9184 mL | |
| 15 mM | 0.2378 mL | 1.1891 mL | 2.3782 mL | 5.9456 mL | |
| 20 mM | 0.1784 mL | 0.8918 mL | 1.7837 mL | 4.4592 mL | |
| 25 mM | 0.1427 mL | 0.7135 mL | 1.4269 mL | 3.5674 mL | |
| 30 mM | 0.1189 mL | 0.5946 mL | 1.1891 mL | 2.9728 mL | |
| 40 mM | 0.0892 mL | 0.4459 mL | 0.8918 mL | 2.2296 mL | |
| 50 mM | 0.0713 mL | 0.3567 mL | 0.7135 mL | 1.7837 mL | |
| 60 mM | 0.0595 mL | 0.2973 mL | 0.5946 mL | 1.4864 mL | |
| 80 mM | 0.0446 mL | 0.2230 mL | 0.4459 mL | 1.1148 mL | |
| 100 mM | 0.0357 mL | 0.1784 mL | 0.3567 mL | 0.8918 mL |
PXS-5505 free base Related Classifications
HY-138625 Related Classifications
Powered by Bioz